Axogen (AXGN) vs TransMedics Group (TMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Axogen (AXGN) has outperformed TransMedics Group (TMDX) over the past year, gaining 113.3% versus a loss of 29.6%. Over five years, TMDX leads with a +205.3% price change compared with +164.6% for AXGN. TransMedics Group is the larger company by market cap ($2.74 billion vs $2.12 billion), about 1.3 times the size.
On valuation, TransMedics Group trades at a lower forward P/E (35.0x vs 52.6x for Axogen).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXGN | TMDX |
|---|---|---|
| Share price | $36.18 | $79.00 |
| Market cap | $2.12B | $2.74B |
| 1-day change | +0.39% | -2.55% |
| YTD return | +10.11% | -33.36% |
| 1-year return | +113.25% | -29.61% |
| 5-year return | +164.61% | +205.35% |
| P/E ratio (TTM) | — | 20.47 |
| Forward P/E | 52.59 | 35.05 |
| EPS (TTM) | $-0.67 | $3.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $605.49M |
| Revenue growth (YoY) | — | +37.13% |
| Net income (latest FY) | — | $190.29M |
| Gross margin | — | 59.92% |
| Operating margin | — | 17.93% |
| Net margin | — | 31.43% |
| 52-week high | $52.91 | $156.00 |
| 52-week low | $15.27 | $60.11 |
| Distance from 52-week high | -31.62% | -49.36% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +48.76% | +26.35% |
| Average volume | 1.23M | 815.54K |
| Shares outstanding | 58.67M | 34.68M |
| Employees | 622 | 898 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AXGN has outperformed TMDX by 142.9 percentage points over the past year.
About Axogen
AXGN stock →Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 622 employees
About TransMedics Group
TMDX stock →TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 898 employees
AXGN vs TMDX FAQ
Which is bigger, Axogen or TransMedics Group?
TransMedics Group (TMDX) is larger, with a market capitalization of $2.74B compared with $2.12B for Axogen (AXGN).
Which stock has performed better over the past year, AXGN or TMDX?
AXGN returned +113.25% over the past 12 months, compared with -29.61% for TMDX (price return, excluding dividends). Past performance does not predict future results.
Are Axogen and TransMedics Group in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.